Using a new approach to adjuvant design we have identified a molecular based adjuvant that enhances immune response by several criteria including, an earlier response, a stronger response to more parts of the vaccine, and the ability to respond to very small amounts of vaccine. Phase I of this project involves applying the same technology to HIV-1 antigens. Phase II of the project will entail optimizing large-scale production of our adjuvant for studies in larger animals and eventual testing in human clinical trials.
Public Health Relevance: This project seeks to further characterize a novel vaccine adjuvant that we have discovered that appears to enhance immune responses to difficult targets. Once this adjuvant has been validated against HIV-1 targets, the long-term goal for benefiting public health will be to use this adjuvant to improve vaccine strategies that target other infectious diseases such as Influenza and Malaria in addition to improving therapeutic vaccine approaches for cancer patients.
Thesaurus Terms: 55 Kda Erythrocyte Membrane Protein; Aids; Aids Antibodies; Aids Antigens; Aids Virus; Atgn; Acquired Immune Deficiency; Acquired Immune Deficiency Syndrome; Acquired Immune Deficiency Syndrome Virus; Acquired Immuno-Deficiency Syndrome; Acquired Immunodeficiency Syndrome; Acquired Immunodeficiency Syndrome Virus; Adjuvant; Adjuvant Study; Adjuvant Trials; Animals; Antibodies; Antibody Formation; Antibody Production; Antibody Repertoire; Antibody Response; Antibody Specificity; Antigenic Determinants; Antigenic Diversity; Antigens; Autoantibodies; Autoimmune Status; Autoimmunity; B Blood Cells; B-Cells; B-Lymphocytes; Binding; Binding (Molecular Function); Binding Determinants; Biological; Blood Serum; Bursa-Dependent Lymphocytes; Bursa-Equivalent Lymphocyte; Cdr3-Region; Cancer Patient; Cardiolipins; Cell Communication And Signaling; Cell Signaling; Cells; Clinical Trials; Clinical Trials, Unspecified; Communicable Diseases; Development; Dose; Emp55; Envelope Glycoprotein Gp160, Hiv; Epitopes; Erythrocyte Membrane Protein P55; Exposure To; Future; Gagging; Gene Products, Gag; Generations; Goals; Grippe; Hiv; Hiv Antibodies; Hiv Antigens; Hiv Envelope Protein Gp160; Hiv Envelope Protein Gp41; Hiv Infections; Hiv Transmembrane Protein Gp41; Hiv Envelope Protein; Hiv-1; Hiv-1 Envelope Protein Gp41; Hiv-Associated Antibodies; Hiv-Associated Antigens; Hiv-I; Hiv1; Htlv-Iii; Htlv-Iii Antibodies; Htlv-Iii Antigens; Htlv-Iii Infections; Htlv-Iii Gp160; Htlv-Iii Gp41; Htlv-Iii-Lav Antibodies; Htlv-Iii-Lav Antigens; Htlv-Iii-Lav Infections; Hemagglutinin; Human; Human Immunodeficiency Viruses; Human T-Cell Leukemia Virus Type Iii; Human T-Cell Lymphotropic Virus Type Iii; Human T-Lymphotropic Virus Type Iii; Human Immunodeficiency Virus 1; Human, General; Immune Response; Immune System; Immunity; Immunization; Immunodeficiency Virus Type 1, Human; Immunologic Deficiency Syndrome, Acquired; Immunologic Stimulation; Immunological Stimulation; Immunostimulation; Individual; Infectious Disease Pathway; Infectious Diseases; Infectious Diseases And Manifestations; Infectious Disorder; Inflammatory; Influenza; Infusion; Infusion Procedures; Intracellular Communication And Signaling; Isoforms; Lav Antibodies; Lav Antigens; Lav-Htlv-Iii; Lymphadenopathy-Associated Antibodies; Lymphadenopathy-Associated Antigens; Lymphadenopathy-Associated Virus; Lymphoid; Lymphoid Cell; Mpp1 Protein, Human; Malaria; Mammals, Mice; Man (Taxonomy); Man, Modern; Mice; Moab, Clinical Treatment; Molecular; Molecular Interaction; Monoclonal Antibodies; Murine; Mus; Oils; Pemp; Palmitoylated Membrane Protein 1; Palmitoylated Membrane Protein 1 55kd; Paludism; Patients; Pattern; Phase; Plasmodium Infections; Preparation; Procedures; Production; Protein Isoforms; Proteins; Public Health; Reflex, Pharyngeal; Relaxation; Retroviral Antigen Gag Protein; Self Tolerance; Sensitization, Immunologic; Sensitization, Immunological; Serum; Signal Transduction; Signal Transduction Systems; Signaling; Specificity; T-Cells; T-Lymphocyte; T-Lymphotropic Virus Type Iii Antibodies, Human; T-Lymphotropic Virus Type Iii Antigens, Human; T-Lymphotropic Virus Type Iii Infections, Human; Technology; Testing; Therapeutic; Thymus-Dependent Lymphocytes; To Autoantigen; Up-Regulation; Up-Regulation (Physiology); Upregulation; Vaccination; Vaccine Adjuvant; Vaccine Antigen; Vaccine Design; Vaccines; Variant; Variation; Viral Gag Proteins; Virus; Virus-Hiv; Viruses, General; Anergy; Antibody Biosynthesis; Autoimmune Antibody; Autoreactive B Cell; Base; Biological Signal Transduction; Body System, Allergic/Immunologic; Clinical Investigation; Complementarity-Determining Region 3; Design; Designing; Efficacy Testing; Env Protein Gp160, Hiv; Env Protein Gp41, Hiv; Experience; Flu Infection; Gag Antigens; Gag Gene Products; Gag Polyproteins; Gag Protein; Gene Product; Gp160; Gp160(Hiv); Gp41(Hiv); Group Specific Antigen; Host Response; Human Mpp1 Protein; Human T Cell Leukemia Virus Iii; Human T Lymphotropic Virus Iii; Immunogen; Immunogenic; Immunoglobulin Biosynthesis; Immunoresponse; Improved; In Vivo; Influenza Infection; Large Scale Production; Membrane Protein, Palmitoylated 1, 55kda, Human; Neutralizing Antibody; Neutralizing Mab; Neutralizing Monoclonal Antibodies; New Approaches; New Vaccines; Next Generation Vaccines; Novel; Novel Approaches; Novel Strategies; Novel Strategy; Novel Vaccines; Organ System, Allergic/Immunologic; P55; Palmitoylated Erythrocyte Membrane Protein P55, Human; Peripheral Tolerance; Prophylactic; Protocol, Adjuvant; Public Health Medicine (Field); Public Health Relevance; Response; Self Reactive Antibody; Self Recognition (Immune); Therapeutic Vaccine; Third Complementarity-Determining Region; Thymus Derived Lymphocyte
